Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.
Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.
Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient’s cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning.
Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.
Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.